Inclusion Criteria

DISEASE CHARACTERISTICS:

- Radiographically confirmed brain metastases with histopathologically confirmed
primary non-small cell lung cancer that will benefit from whole-brain radiotherapy

- Must have ≥ 1 measurable intracranial site of disease, according to RECIST criteria,
that has not been previously treated with stereotactic radiation

- Must have stable extracranial disease for 4 weeks

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy ≥ 12 weeks

- ANC > 1,500/mm³

- Platelets > 100,000/mm³

- Hemoglobin > 11 g

- BUN ≤ 25 mg

- Serum creatinine < 1.5 times upper limit of normal (ULN)

- Serum bilirubin ≤ 1.5 times ULN

- Serum transaminases ≤ 2 times ULN (< 5 times ULN if patient has liver metastases)

- Cholesterol ≤ 300 mg/dL

- Triglycerides ≤ 2.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for ≥ 3 months after
completion of study treatment

- No other malignancies within the past 3 years, except for adequately treated
carcinoma in situ of the cervix or basal or squamous cell carcinomas of the skin

- No severe and/or uncontrolled medical conditions or other conditions that could
affect participation in the study, including any of the following:

- Unstable angina pectoris, symptomatic congestive heart failure, myocardial
infarction within the past 6 months, or serious uncontrolled cardiac arrhythmia

- Severely impaired lung function (i.e., FEV1 < 0.8 cc)

- Uncontrolled diabetes as defined by fasting serum glucose ≥ 1.5 times ULN

- Any active (acute or chronic) or uncontrolled infection/disorders

- Non-malignant medical illnesses that are uncontrolled or whose control may be
jeopardized by the treatment with the study therapy

- Liver disease, such as cirrhosis, chronic active hepatitis, or chronic
persistent hepatitis

- No known history of HIV seropositivity

- No impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of everolimus (e.g., ulcerative disease,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
resection)

- No active, bleeding diathesis

- No known hypersensitivity to everolimus or other rapamycin (i.e., sirolimus,
temsirolimus) or to its excipients

- No history of noncompliance to medical regimens

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from the acute toxicities of any prior therapy

- Prior surgical resection of a brain metastasis allowed

- The extent of surgical resection in patients having prior resection of 1 of
multiple metastases shall be documented as a biopsy, subtotal resection, or
total resection as described by the operative report and/or post-operative
imaging

- At least 3 weeks since prior major surgery or completion of extracranial radiation

- At least 3 weeks since prior and no concurrent systemic anticancer therapy, other
than the study medications administered as part of this study protocol

- At least 6 weeks since prior nitrosoureas

- More than 1 week since prior and no concurrent immunization with attenuated live
vaccines

- More than 3 weeks since prior chemotherapy

- No prior brain radiotherapy of any form

- No concurrent chronic treatment with systemic steroids or other immunosuppressive
agents, except steroids for neurological stability following the diagnosis of brain
metastases

- No prior treatment with an mTOR inhibitor

- No concurrent anti-vitamin K medication, except low dose coumarin

- No concurrent drugs or substances known to be inhibitors or inducers of the isoenzyme
CYP3A

- No other concurrent investigational therapy